Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04931654 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | active not recruiting | Phase 1 / Phase 2 | 136 | AstraZenecaINDUSTRY | 10 | Oct 9, 2025 | clinicaltrials |
| NCT04711330 | Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy(Prediction) | active not recruiting | — | 126 | Leiden University Medical CenterOTHER | 2 | Oct 6, 2025 |
| clinicaltrials |
| NCT05598853 | Intrathecal Double Checkpoint Inhibition(IT-IO) | active not recruiting | Phase 1 | 26 | University of ZurichOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04986670 | NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer | active not recruiting | N/A | 299 | Tufts UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05949619 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05020457 | SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. | active not recruiting | Phase 2 | 69 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05020769 | SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. | active not recruiting | Phase 2 / Phase 3 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05163028 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | active not recruiting | Phase 1 | 42 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05485974 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | active not recruiting | Phase 1 | 44 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT06448910 | Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC | active not recruiting | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT03289780 | Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects(INSIGHT) | active not recruiting | — | 5,006 | Biodesix, Inc.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04171492 | Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules(ALTITUDE) | active not recruiting | — | 2,000 | Biodesix, Inc.INDUSTRY | 2 | Sep 19, 2025 | clinicaltrials |
| NCT05880706 | A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 198 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT02788461 | Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy(PET-BOOST) | active not recruiting | N/A | 78 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03306680 | SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial | active not recruiting | Phase 1 | 30 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03485378 | Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease(ASPIRE-ILD) | active not recruiting | N/A | 39 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 18, 2025 | clinicaltrials |
| NCT04547504 | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %(PERSEE) | active not recruiting | Phase 3 | 349 | University Hospital, BrestOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT06020066 | SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI | active not recruiting | Phase 2 | 202 | Fudan UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT02617186 | Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: RCT | active not recruiting | N/A | 446 | St. Joseph's Healthcare HamiltonOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05091190 | Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers(MADMAS) | active not recruiting | N/A | 75 | Hospices Civils de LyonOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04946279 | Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer | active not recruiting | N/A | 98 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05318573 | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 120 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06505837 | JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） | active not recruiting | Phase 3 | 395 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT04495153 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | active not recruiting | Phase 2 | 90 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT03620669 | 1st Line Durvalumab in PS 2 NSCLC Patients | active not recruiting | Phase 2 | 48 | Swiss Cancer InstituteOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05787613 | A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients | active not recruiting | Phase 2 | 132 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05049044 | Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)(OBSTINATE) | active not recruiting | — | 413 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Aug 4, 2025 | clinicaltrials |
| NCT05078931 | A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients | active not recruiting | Phase 2 | 35 | Shanghai Chest HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03753685 | X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases | active not recruiting | Phase 2 | 27 | Fudan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05894889 | Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC | active not recruiting | Phase 2 | 70 | Peking UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07076693 | Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） | active not recruiting | Phase 2 / Phase 3 | 97 | Shanghai Chest HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05195619 | Personalized DC Vaccines in Non Small Cell Lung Cancer | active not recruiting | Phase 1 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02284308 | Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy(ELDAPT) | active not recruiting | — | 180 | Maastricht Radiation OncologyOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05943795 | A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma | active not recruiting | Phase 3 | 589 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04175769 | A Nutritional Supplement to Support People With Non-small Cell Lung Cancer | active not recruiting | N/A | 9 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05116462 | Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | active not recruiting | Phase 3 | 506 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04676477 | HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 246 | Daiichi SankyoINDUSTRY | 4 | Jun 22, 2025 | clinicaltrials |
| NCT05607550 | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | active not recruiting | Phase 3 | 398 | ArriVent BioPharma, Inc.INDUSTRY | 19 | Jun 22, 2025 | clinicaltrials |
| NCT07024862 | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy | active not recruiting | — | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | BioAtla, Inc.INDUSTRY | 2 | Jun 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 9, 2025source: clinicaltrials